{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:20:40Z","timestamp":1787066440927,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82272736,81460460,81760542"],"award-info":[{"award-number":["82272736,81460460,81760542"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009329","name":"Scientific Research and Technology Development Program of Guangxi Zhuang Autonomous Region","doi-asserted-by":"publisher","award":["2023GXNSFDA026009\uff0c2016GXNSFAA380252, 2018AB61001 and 2014GXNSFBA118114"],"award-info":[{"award-number":["2023GXNSFDA026009\uff0c2016GXNSFAA380252, 2018AB61001 and 2014GXNSFBA118114"]}],"id":[{"id":"10.13039\/501100009329","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Research Foundation of the Health Department of Guangxi Province","award":["No.S2018087"],"award-info":[{"award-number":["No.S2018087"]}]},{"name":"Guangxi Medical University Training Program for Distinguished Young Scholars","award":["2017"],"award-info":[{"award-number":["2017"]}]},{"name":"Medical Excellence Award Funded by the Creative Research Development Grant from the First Affiliated Hospital of Guangxi Medical University","award":["2016"],"award-info":[{"award-number":["2016"]}]},{"DOI":"10.13039\/501100017282","name":"Guangxi Overseas High\u2010level Talent \u201cHundred People Program\u201d","doi-asserted-by":"publisher","award":["ZY18057006"],"award-info":[{"award-number":["ZY18057006"]}],"id":[{"id":"10.13039\/501100017282","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00405-024-08768-w","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T16:24:40Z","timestamp":1719246280000},"page":"5111-5118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immune checkpoint inhibitor combined with chemotherapy versus chemotherapy alone in the first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a meta-analysis of random controlled trials"],"prefix":"10.1007","volume":"281","author":[{"given":"Shuangyue","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2287-8757","authenticated-orcid":false,"given":"Min","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"key":"8768_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"Y-P Chen","year":"2019","unstructured":"Chen Y-P, Chan ATC, Le Q-T et al (2019) Nasopharyngeal carcinoma. Lancet 394:64\u201380. https:\/\/doi.org\/10.1016\/S0140-6736(19)30956-0","journal-title":"Lancet"},{"key":"8768_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"8768_CR3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","volume":"18","author":"KCW Wong","year":"2021","unstructured":"Wong KCW, Hui EP, Lo K-W et al (2021) Nasopharyngeal carcinoma: an evolving paradigm. Nat Rev Clin Oncol 18:679\u2013695. https:\/\/doi.org\/10.1038\/s41571-021-00524-x","journal-title":"Nat Rev Clin Oncol"},{"key":"8768_CR4","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/S0140-6736(16)31388-5","volume":"388","author":"L Zhang","year":"2016","unstructured":"Zhang L, Huang Y, Hong S et al (2016) Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet 388:1883\u20131892. https:\/\/doi.org\/10.1016\/S0140-6736(16)31388-5","journal-title":"Lancet"},{"key":"8768_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12935-019-0863-5","volume":"19","author":"Z-L Huang","year":"2019","unstructured":"Huang Z-L, Liu S, Wang G-N et al (2019) The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. Cancer Cell Int 19:141. https:\/\/doi.org\/10.1186\/s12935-019-0863-5","journal-title":"Cancer Cell Int"},{"key":"8768_CR6","doi-asserted-by":"publisher","first-page":"175883592210962","DOI":"10.1177\/17588359221096214","volume":"14","author":"J-Y Xu","year":"2022","unstructured":"Xu J-Y, Wei X-L, Wang Y-Q, Wang F-H (2022) Current status and advances of immunotherapy in nasopharyngeal carcinoma. Ther Adv Med Oncol 14:17588359221096214. https:\/\/doi.org\/10.1177\/17588359221096214","journal-title":"Ther Adv Med Oncol"},{"key":"8768_CR7","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","volume":"22","author":"Y Yang","year":"2021","unstructured":"Yang Y, Qu S, Li J et al (2021) Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 22:1162\u20131174. https:\/\/doi.org\/10.1016\/S1470-2045(21)00302-8","journal-title":"Lancet Oncol"},{"key":"8768_CR8","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","volume":"41","author":"Y Yang","year":"2023","unstructured":"Yang Y, Pan J, Wang H et al (2023) Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309). Cancer Cell 41:1061\u20131072e4. https:\/\/doi.org\/10.1016\/j.ccell.2023.04.014","journal-title":"Cancer Cell"},{"key":"8768_CR9","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1001\/jama.2023.20181","volume":"330","author":"H-Q Mai","year":"2023","unstructured":"Mai H-Q, Chen Q-Y, Chen D et al (2023) Toripalimab Plus Chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 Randomized Clinical Trial. JAMA 330:1961\u20131970. https:\/\/doi.org\/10.1001\/jama.2023.20181","journal-title":"JAMA"},{"key":"8768_CR10","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC et al (2011) The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"8768_CR11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.annonc.2022.12.007","volume":"34","author":"ATC Chan","year":"2023","unstructured":"Chan ATC, Lee VHF, Hong R-L et al (2023) Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial. Ann Oncol 34:251\u2013261. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.007","journal-title":"Ann Oncol"},{"key":"8768_CR12","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","volume":"19","author":"W Fang","year":"2018","unstructured":"Fang W, Yang Y, Ma Y et al (2018) Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol 19:1338\u20131350. https:\/\/doi.org\/10.1016\/S1470-2045(18)30495-9","journal-title":"Lancet Oncol"},{"key":"8768_CR13","doi-asserted-by":"publisher","first-page":"1079515","DOI":"10.3389\/fimmu.2022.1079515","volume":"13","author":"W Li","year":"2022","unstructured":"Li W, Duan X, Chen X et al (2022) Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma. Front Immunol 13:1079515. https:\/\/doi.org\/10.3389\/fimmu.2022.1079515","journal-title":"Front Immunol"},{"key":"8768_CR14","doi-asserted-by":"publisher","first-page":"105127","DOI":"10.1016\/j.oraloncology.2020.105127","volume":"113","author":"D Johnson","year":"2021","unstructured":"Johnson D, Ma BBY (2021) Targeting the PD-1\/ PD-L1 interaction in nasopharyngeal carcinoma. Oral Oncol 113:105127. https:\/\/doi.org\/10.1016\/j.oraloncology.2020.105127","journal-title":"Oral Oncol"},{"key":"8768_CR15","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","volume":"35","author":"C Hsu","year":"2017","unstructured":"Hsu C, Lee S-H, Ejadi S et al (2017) Safety and Antitumor Activity of Pembrolizumab in patients with programmed death-ligand 1-Positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol 35:4050\u20134056. https:\/\/doi.org\/10.1200\/JCO.2017.73.3675","journal-title":"J Clin Oncol"},{"key":"8768_CR16","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","volume":"36","author":"BBY Ma","year":"2018","unstructured":"Ma BBY, Lim W-T, Goh B-C et al (2018) Antitumor Activity of Nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol 36:1412\u20131418. https:\/\/doi.org\/10.1200\/JCO.2017.77.0388","journal-title":"J Clin Oncol"},{"key":"8768_CR17","doi-asserted-by":"publisher","first-page":"e003790","DOI":"10.1136\/jitc-2021-003790","volume":"9","author":"Y Yang","year":"2021","unstructured":"Yang Y, Zhou T, Chen X et al (2021) Efficacy, safety, and biomarker analysis of Camrelizumab in previously treated recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN study). J Immunother Cancer 9:e003790. https:\/\/doi.org\/10.1136\/jitc-2021-003790","journal-title":"J Immunother Cancer"},{"key":"8768_CR18","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1200\/JCO.20.02712","volume":"39","author":"F-H Wang","year":"2021","unstructured":"Wang F-H, Wei X-L, Feng J et al (2021) Efficacy, Safety, and Correlative Biomarkers of Toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02). J Clin Oncol 39:704\u2013712. https:\/\/doi.org\/10.1200\/JCO.20.02712","journal-title":"J Clin Oncol"},{"key":"8768_CR19","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1186\/s12885-023-11318-y","volume":"23","author":"J Luo","year":"2023","unstructured":"Luo J, Xiao W, Hua F et al (2023) Efficacy and safety of PD-1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens: a systematic review and meta-analysis. BMC Cancer 23:1172. https:\/\/doi.org\/10.1186\/s12885-023-11318-y","journal-title":"BMC Cancer"},{"key":"8768_CR20","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/JCO.19.03136","volume":"38","author":"S Gadgeel","year":"2020","unstructured":"Gadgeel S, Rodr\u00edguez-Abreu D, Speranza G et al (2020) Updated analysis from KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for previously untreated metastatic nonsquamous non-small-cell Lung Cancer. J Clin Oncol 38:1505\u20131517. https:\/\/doi.org\/10.1200\/JCO.19.03136","journal-title":"J Clin Oncol"},{"key":"8768_CR21","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","volume":"39","author":"SV Liu","year":"2021","unstructured":"Liu SV, Reck M, Mansfield AS et al (2021) Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung Cancer treated with atezolizumab, carboplatin, and Etoposide (IMpower133). J Clin Oncol 39:619\u2013630. https:\/\/doi.org\/10.1200\/JCO.20.01055","journal-title":"J Clin Oncol"},{"key":"8768_CR22","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"J-M Sun","year":"2021","unstructured":"Sun J-M, Shen L, Shah MA et al (2021) Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 398:759\u2013771. https:\/\/doi.org\/10.1016\/S0140-6736(21)01234-4","journal-title":"Lancet"},{"key":"8768_CR23","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","volume":"32","author":"LA Emens","year":"2021","unstructured":"Emens LA, Adams S, Barrios CH et al (2021) First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol 32:983\u2013993. https:\/\/doi.org\/10.1016\/j.annonc.2021.05.355","journal-title":"Ann Oncol"},{"key":"8768_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398:27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2","journal-title":"Lancet"},{"key":"8768_CR25","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.intimp.2018.12.006","volume":"67","author":"L Sun","year":"2019","unstructured":"Sun L, Chen L, Li H (2019) Checkpoint-modulating immunotherapies in tumor treatment: targets, drugs, and mechanisms. Int Immunopharmacol 67:160\u2013175. https:\/\/doi.org\/10.1016\/j.intimp.2018.12.006","journal-title":"Int Immunopharmacol"},{"key":"8768_CR26","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/annonc\/mdv209","volume":"26","author":"L Apetoh","year":"2015","unstructured":"Apetoh L, Ladoire S, Coukos G, Ghiringhelli F (2015) Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? Ann Oncol 26:1813\u20131823. https:\/\/doi.org\/10.1093\/annonc\/mdv209","journal-title":"Ann Oncol"},{"key":"8768_CR27","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1002\/ijc.32380","volume":"145","author":"R You","year":"2019","unstructured":"You R, Liu Y-P, Lin M et al (2019) Relationship of circulating tumor cells and Epstein-Barr virus DNA to progression-free survival and overall survival in metastatic nasopharyngeal carcinoma patients. Int J Cancer 145:2873\u20132883. https:\/\/doi.org\/10.1002\/ijc.32380","journal-title":"Int J Cancer"},{"key":"8768_CR28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12943-020-01292-5","volume":"20","author":"Y-P Chen","year":"2021","unstructured":"Chen Y-P, Lv J-W, Mao Y-P et al (2021) Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses. Mol Cancer 20:14. https:\/\/doi.org\/10.1186\/s12943-020-01292-5","journal-title":"Mol Cancer"},{"key":"8768_CR29","doi-asserted-by":"publisher","first-page":"1146898","DOI":"10.3389\/fimmu.2023.1146898","volume":"14","author":"X Qian","year":"2023","unstructured":"Qian X, Chen H, Tao Y (2023) Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis. Front Immunol 14:1146898. https:\/\/doi.org\/10.3389\/fimmu.2023.1146898","journal-title":"Front Immunol"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-024-08768-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-024-08768-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-024-08768-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T16:16:54Z","timestamp":1726935414000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-024-08768-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["8768"],"URL":"https:\/\/doi.org\/10.1007\/s00405-024-08768-w","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,24]]},"assertion":[{"value":"18 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}